for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Charles River Laboratories Intl. Inc

CRL

Latest Trade

352.09USD

Change

0.00(-0.00%)

Volume

302,192

Today's Range

350.17

 - 

354.92

52 Week Range

165.76

 - 

354.92

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
352.09
Open
354.83
Volume
302,192
3M AVG Volume
12.92
Today's High
354.92
Today's Low
350.17
52 Week High
354.92
52 Week Low
165.76
Shares Out (MIL)
50.25
Market Cap (MIL)
17,693.51
Forward P/E
35.24
Dividend (Yield %)
--

Next Event

Q2 2021 Charles River Laboratories International Inc Earnings Release

Latest Developments

More

Charles River Laboratories To Acquire Vigene Biosciences For Purchase Price Of $292.5 Mln In Cash

Charles River Laboratories International Inc Files For Potential Mixed Shelf Offering Size Not Disclosed - SEC Filing

Charles River Laboratories Reports Q1 Non GAAP EPS Of $2.53

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Charles River Laboratories Intl. Inc

Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company's clients' manufacturing activities.

Industry

Biotechnology & Drugs

Contact Info

251 Ballardvale St

WILMINGTON, MA

01887-1096

United States

+1.781.2226000

https://www.criver.com/

Executive Leadership

James C. Foster

Chairman of the Board, President, Chief Executive Officer

David Ross Smith

Chief Financial Officer, Corporate Executive Vice President

William D. Barbo

Corporate Executive Vice President and Chief Commercial Officer

Birgit Girshick

Corporate Executive Vice President, Global Discovery and Safety Assessment, Biologics and Avian

Joseph W. LaPlume

Corporate Executive Vice President, Corporate Development and Strategy

Key Stats

1.81 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

2.3K

2019

2.6K

2020

2.9K

2021(E)

3.5K
EPS (USD)

2018

6.030

2019

6.730

2020

8.130

2021(E)

9.978
Price To Earnings (TTM)
47.80
Price To Sales (TTM)
5.82
Price To Book (MRQ)
8.10
Price To Cash Flow (TTM)
28.65
Total Debt To Equity (MRQ)
100.98
LT Debt To Equity (MRQ)
100.84
Return on Investment (TTM)
8.00
Return on Equity (TTM)
6.87

Latest News

Latest News

S.C. horseshoe crab harvest for pharma can proceed - 4th Circuit

A federal appeals court has allowed the harvesting in a South Carolina national refuge of horseshoe crabs whose blood is used to test the safety of vaccines, a Monday court filing shows.

BRIEF-Charles River Laboratories Increases Size Of Board To 12

Charles River Laboratories International Inc:

Blue-blooded crabs at heart of pharma dispute on drug testing

If you've received a vaccination, hip replacement or chemotherapy without suffering toxic shock, chances are you've benefited from a vast bloodletting of horseshoe crabs.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up